HomeStartups NovoCure lifecycle

Claimed by owner Last Update Jun 10, 2026 Suggest Edits Claim Profile

Claimed by owner

NovoCure

Treatment of Brain Tumors Using Electric Fields

PUBLIC on NASDAQ on Oct, 2015

NovoCure

NovoCure Overview

Cumulative Funding Raised Over Time ($)

Employees Over Time

Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?

CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing

Frank Leonard’s Board Appointment and Insider Selling Might Change The Case For Investing In NovoCure (NVCR)

Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More

3 Overlooked Stocks Set to Soar in 2026

International Markets and NovoCure (NVCR): A Deep Dive for Investors

NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next Entry

NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

NovoCure Limited Q1 2026 Earnings Call Summary

NovoCure (NVCR) Q1 2026 Earnings Transcript

Novocure Reports First Quarter 2026 Financial Results

Sector Update: Health Care Stocks Gain Thursday Afternoon

Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out

NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates

NovoCure Q1 Earnings Call Highlights

NovoCure (NVCR) Is Down 6.6% After Strong PANOVA-4 Phase 2 Data In Metastatic Pancreatic Cancer – Has The Bull Case Changed?

Novocure to Report First Quarter 2026 Financial Results

השקעת הבריאות של ביל אקמן וההפתעה שמנכ"ל אלי לילי לא צפה

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

Is NovoCure (NVCR) Now Pricing In Too Much Pessimism After Prolonged Share Price Slump

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates

Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment

NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know

Novocure Announces Optune LuaÂ® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

#Product Stage #Customers

A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations

#Product Stage #Public Trading

Novocure to Participate in 2026 Leerink Global Healthcare Conference

NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Plans ...

#FDA approved/pending approval #Management Changes #Product Stage #Customers

NovoCure Limited Q4 2025 Earnings Call Summary

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

#Product Stage #Customers #Partners

NovoCure: Q4 Earnings Snapshot

NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates

NovoCure Q4 Earnings Call Highlights

#Product Stage #Management Changes #Customers

Stock Market Today, Feb. 25: Nasdaq Gains 1.3% As Nvidia Reignites AI Optimism

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

#Customers #Partners

Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know

Novocure Gains FDA Approval for Optune Pax to Treat Pancreatic Cancer

#FDA approved/pending approval

Novocureâ€™s stock rises 37% on FDA clearance of pancreatic cancer treatment device

#Product Stage #Public Trading

Soleus Adds a Significant Number of Celcuity Shares

#Investment

NovoCure (NVCR) Is Up 23.6% After Landmark FDA Nod For Optune Pax In Pancreatic Cancer

#Product Stage #FDA approved/pending approval

Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs

#Product Stage #Acquisition

Assessing NovoCure (NVCR) Valuation After FDA Approval Of Optune Pax For Pancreatic Cancer

#Product Stage #Public Trading

Novocure's share price jumped after it announced FDA approval for its device for treating pancreatic cancer with electric fields.

#FDA approved #Product Stage #Public Trading

מניית החברה נוסקת בוול סטריט בעקבות אישור שקיבלה חברת נובוקיור מה-FDA ● החברה פיתחה ומשווקת מוצר לטיפול לטיפול בסרטן הלבלב באמצעות שדות חשמליים

#FDA approved/pending approval #Management Changes

These Stocks Are Today’s Movers: AppLovin, Fastly, Micron, Cisco, QuantumScape, Novocure, Cognex, Crocs, and More

Stocks to Watch Thursday: Cisco, McDonald's, AppLovin

Sector Update: Health Care Stocks Rise Late Afternoon

Sector Update: Health Care Stocks Higher Thursday Afternoon

Novocure Is Up 30%. FDA Approval Is Giving the Biotech Stock a Lift.

#FDA approved/pending approval

U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

#Product Stage #FDA approved/pending approval

Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar

#FDA approved/pending approval

Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer

#Management Changes

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

#Customers #Partners

Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock?

NovoCure (NVCR): Assessing Valuation After a Recent Rebound From Multi‑Month Lows

Has NovoCure’s Tumor Treating Fields Progress Created a Value Opportunity After the 2025 Share Slump?

NovoCure (NVCR) Q3 2024 Earnings Call Transcript

#FDA approved #Management Changes

NovoCure (NVCR) Q4 2024 Earnings Call Transcript

#Product Stage #Customers #FDA approved/pending approval #Management Changes

Novocure (NVCR) Q2 2025 Earnings Call Transcript

#Product Stage #Customers #Investment

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Medtronic changes investor relations leadership ahead of diabetes spinout

#Management Changes #Public Trading

Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change?

#Management Changes

Is NovoCure’s 93% Five Year Share Price Slide Now Creating an Opportunity in 2025?

#Product Stage

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

#Management Changes

NovoCure (NVCR) Q3 2025 Earnings Call Transcript

#Product Stage #Customers #FDA approved/pending approval

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

#Product Stage #Management Changes

NovoCure (NVCR) Valuation Discount Contrasts With Persistent Losses and Unprofitability Challenges

#Product Stage #Customers

Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NovoCure: Q3 Earnings Snapshot

NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges

#Product Stage #Customers

Novocure Reports Third Quarter 2025 Financial Results

#Customers #Partners #Product Stage

NovoCure (NVCR): Evaluating Valuation as Share Price Stabilizes After Recent Volatility

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

#Product Stage

Novocure to Report Third Quarter 2025 Financial Results

#Product Stage #Public Trading

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

#Product Stage #FDA approved/pending approval

Novocure obtains approval for Optune Lua device in Japan to treat NSCLC

#FDA approved/pending approval

Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

#FDA approved/pending approval

NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo

#Product Stage

Insider Spends US$997k Buying More Shares In NovoCure

NovoCure (NVCR) Is Up 5.4% After Spain Reimburses TTFields Therapy—Has The Bull Case Changed?

#Product Stage #FDA approved/pending approval #Customers

2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts

Novocure Announces Upcoming Investor Events

#Management Changes

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

#Customers

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

#Product Stage #FDA approved/pending approval

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

#Product Stage #FDA approved/pending approval

Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)

#Customers

NovoCure Second Quarter 2025 Earnings: Beats Expectations

NovoCure: Q2 Earnings Snapshot

NovoCure (NVCR) Reports Q2 Earnings: What Key Metrics Have to Say

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

Novocure Reports Second Quarter 2025 Financial Results

#Product Stage #Customers #Partners

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

#Product Stage

Novocure to Report Second Quarter 2025 Financial Results

#Product Stage #Public Trading

Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year loss

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?

What Makes NovoCure (NVCR) a New Buy Stock

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

#Product Stage

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

#Product Stage

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

#Product Stage #FDA approved/pending approval

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street

#Product Stage #Customers #FDA approved/pending approval

Novocure Announces Upcoming Investor Events

#Product Stage #Management Changes

The Next Frontier to Treat Cancer: Electricity

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?

Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

Why NovoCure Stock Skyrocketed This Week

#Product Stage #Customers

Why NovoCure Stock Leaped 4% Higher Today

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

NovoCure: Q1 Earnings Snapshot

Novocure Reports First Quarter 2025 Financial Results

#Product Stage #Customers #Partners

NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

#Product Stage

Novocure’s device for metastatic NSCLC treatment gains CE Mark

#Product Stage #FDA approved/pending approval

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

#Product Stage #FDA approved/pending approval

Sector Update: Health Care Stocks Rise Late Afternoon

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Why NovoCure Stock Was Withering on Wednesday

Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?

Novocure to Report First Quarter 2025 Financial Results

#Public Trading

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

#Management Changes

NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...

#Product Stage #Customers #FDA approved/pending approval

NovoCure Full Year 2024 Earnings: EPS Misses Expectations

NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say

NovoCure (NVCR) Q4 2024 Earnings Call Transcript

#FDA approved #Customers #Management Changes #Expand

NovoCure: Q4 Earnings Snapshot

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

#Product Stage #Customers #Partners #FDA approved/pending approval

NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Luxury hotels group Firmdale has sold 20% stake to Swedish pharma tycoon

#Investment #Acquisition

Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 85% gain

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

#Customers #Partners

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Novocure price target raised to $42 from $28 at Piper Sandler

Why NovoCure Stock Was Winning Big This Week

#Partners

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

#Customers #Partners

NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint

#Partners

Novocure Stock Earns 96 RS Rating

נובוקיור קפצה ב-49% לאחר הצלחה בניסוי להארכת חיי החולים בסרטן הלבלב

Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date

#Customers #Partners #Management Changes

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success

#Customers #Management Changes

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

#Customers #Partners

Novocure seeks approval after pancreatic cancer wearable scores at Phase III

#Customers #Partners

Novocure to Participate in Upcoming Investor Conferences

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure secures FDA approval for add-ons to brain cancer treatment wearable

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

NovoCure (NVCR) Q3 2024 Earnings Call Transcript

#Customers #Management Changes #Expand

NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...

NovoCure’s Strong Q3 and Leadership Changes in 2024

#Management Changes

NovoCure: Q3 Earnings Snapshot

Novocure Reports Third Quarter 2024 Financial Results

#Customers #Partners #Management Changes

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

Novocure Appoints Christoph Brackmann as Chief Financial Officer

#Management Changes

Novocure Reports Third Quarter 2024 Financial Results

#Customers #Partners #Management Changes

Novocure Appoints Christoph Brackmann as Chief Financial Officer

#Management Changes

Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment

NovoCure scoops FDA approval on wearable for metastatic cancer treatment

Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment

NovoCure scoops FDA approval on wearable for metastatic cancer treatment

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

Novocure wins FDA approval for electric field device in lung cancer

Novocure shares soar 33% as FDA approves lung cancer treatment

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer

#Customers #Layoffs #Management Changes

Novocure to Report Third Quarter 2024 Financial Results

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Why NovoCure Stock Dived by 13% This Week

#Management Changes

NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor

Novocure Announces Planned CEO Transition

NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor

Novocure Announces Planned CEO Transition

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

Biotech stocks: Which drugmakers are worth a buy?

Even after rising 8.9% this past week, NovoCure (NASDAQ:NVCR) shareholders are still down 86% over the past three years

New Strong Buy Stocks for August 1st

#None

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade

NovoCure: Q2 Earnings Snapshot

#Investment

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

NovoCure (NVCR) Q2 2024 Earnings Call Transcript

#Customers #Expand

Novocure Reports Second Quarter 2024 Financial Results

Novocure to Report Second Quarter 2024 Financial Results

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025

#Investment

NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript

#Customers #Investment

NovoCure (NVCR) Q1 2024 Earnings Call Transcript

#Customers #Investment #Expand

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

Novocure Reports First Quarter 2024 Financial Results

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

#Public Trading

NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported

NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Novocure to Report First Quarter 2024 Financial Results

NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade

Why NovoCure Stock Soared 18.3% This Week

NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?

#Investment

Why Novocure Stock Is Jumping Today

#Customers #Management Changes

UPDATE 1-Novocure's lung cancer therapy succeeds in late-stage trial

#Customers

Novocure's device shown to slow cancer progression in the brain in trial

#Customers

Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish

#Customers

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?

#Investment

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

Is NovoCure Limited (NASDAQ:NVCR) Worth US$16.0 Based On Its Intrinsic Value?

#Investment

NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript

#Customers #Management Changes #Expand

NovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023

#Customers #Investment

NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates

#Investment

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

NovoCure (NVCR) Q4 2023 Earnings Call Transcript

#Customers #Investment #Management Changes #Expand

Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength?

#Investment

Why Is Cancer Focused Novocure Stock Trading Higher Today?

#Customers

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?

#Investment

Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know

#Public Trading

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Oncology co NovoCure to lay off 200

#Layoffs #Management Changes

15 Best Falling Stocks To Buy Now

#Investment

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability

Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference

NovoCure Limited (NASDAQ:NVCR) institutional owners may be pleased with recent gains after 85% loss over the past year

#Investment

11 Best Undervalued UK Stocks To Buy Now

#Investment

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

Is Novocure Stock a Buy?

The NovoCure Ltd (NVCR) Company: A Short SWOT Analysis

#Customers #Partners #Management Changes

NovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Call Transcript

#Management Changes, Investment

NovoCure (NVCR) Q3 2023 Earnings Call Transcript

NovoCure Ltd (NVCR) Reports Q3 2023 Financial Results

#Customers

Novocure Reports Third Quarter 2023 Financial Results

Why Novocure Stock Was Sick Today

NovoCure (NVCR) Reports Q3 Loss, Misses Revenue Estimates

#Investment, Management Changes

Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

NovoCure (NASDAQ:NVCR investor three-year losses grow to 90% as the stock sheds US$229m this past week

#Customers #Investment

Novocure to Report Third Quarter 2023 Financial Results

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

Should You Hold NovoCure Limited (NVCR)?

#Investment

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer

3 Healthcare Stocks to Sell in September Before They Crash & Burn

Down 31% in 1 Day, What's Next for NovoCure Stock?

Is NovoCure's Stock Headed for a Free Fall?

Why Novocure Stock Fell 24.4% This Week

Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Midday movers: 3M, XPeng, Hawaiian Electric Industries and more

Novocure Plummets 38% After Its Treatment For Ovarian Cancer Fails

NovoCure Ltd (NVCR): A Deep Dive into Its Performance Potential

NovoCure (NVCR): A Smart Investment or a Value Trap? An In-Depth Exploration

Why NovoCure Stock Is Crashing Today

Novocure Shares Plunge After Its Ovarian Cancer Treatment Fails to Meet Goal

Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer

Could NovoCure Stock Help You Become a Millionaire?

Novocure to Participate in Upcoming Investor Conferences

Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod

15 Worst Performing Healthcare Stocks in 2023

Is NovoCure Stock a Buy Now?

#Customers, Expand

2 Incredibly Cheap Growth Stocks to Buy in August

Why Novocure Was a Healthy Stock Today

DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls

Apple downgraded, Amazon upgraded: Wall Street's top analyst calls

10 Oversold NASDAQ Stocks to Buy

Novocure Reports Second Quarter 2023 Financial Results

Why Novocure Stock Tumbled by Nearly 16% Today

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

NovoCure (NVCR) Q2 2023 Earnings Call Transcript

Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

Novocure to Report Second Quarter 2023 Financial Results

3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon

This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street

Novocure Breaks a Major Support Zone: What Now?

Why Shares of Zai Lab Are Dropping Wednesday

UPDATE 2-Novocure's lung cancer device extends survival in late-stage study

Novocure Crashes 43% As Critics Question Its 'Profound' Impact In Lung Cancer Treatment

#Customers

These 2 Nasdaq Stocks Are Plunging. Here's Why

Why NovoCure Stock Is Crashing Today

LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Novocure Stock Gets Relative Strength Rating Upgrade, Then Drops +40%

Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts

#Customers, Partners

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education

3 No-Brainer Stocks to Buy for Under $100 Right Now

השבוע בביומד: נובוקיור שיכנעה את השוק שמגמת הירידה זמנית

Should You Buy Novocure Stock Right Now?

NovoCure Limited's (NASDAQ:NVCR) Business Is Trailing The Industry But Its Shares Aren't

NovoCure (NVCR) Q1 2023 Earnings Call Transcript

Novocure Reports First Quarter 2023 Financial Results

NovoCure (NVCR) Reports Q1 Loss, Lags Revenue Estimates

Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

#Customers

The 3 Most Promising Healthcare Tech Stocks for April 2023

Novocure shakes up C-suite after successful trial of tumor-treating electric fields in lung cancer

Novocure Announces Organizational Changes to Prepare for Future Growth

#Management Changes

Novocure Reports Second Quarter 2022 Financial Results

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer

Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer

Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer

נובוקיור הפכה לחברה הישראלית בעלת השווי הגבוה ביותר

"One day every cancer patient will use our product"

Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting

Novocure nets European approval for its Tumor Treating Fields therapy in mesothelioma, raises cash for commercial expansion

#Investment #Expand

Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

#Partners

China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China

Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma

German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune's Survival Benefit for Patients with Newly Diagnosed Glioblastoma

FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma

Medicare contractors finalize narrow coverage for glioblastoma treatment

Brain tumor treatment co NovoCure worth $4.7b

#Public Trading #Investment

Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019

Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019

Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role

#Management Changes

Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

Novocure backs $2m in brain cancer research grants

Novocure Announces Addition to Its Board of Directors

Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma

Oncology co Novocure raises $150m debt

#Investment

Novocure Secures New $150 Million Non-Dilutive Term Loan Financing - Novocure

Novocure™ Announces National Reimbursement for Optune® in Austria

Celgene adds Novocure's noninvasive brain cancer device to combo drug trial

#Partners

Novocure files for $300m Nasdaq IPO

#Investment #Public Trading

Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors

Similar Companies

Driven by Finder AI

Primary sector

Total funding

Undisclosed

Funding stage

undefined

Number of employees

Founded

4/1999

Team Members

undefined

Contact Team

Affiliated Organizations

(undefined)

Locations

Israel

Photos & videos

(0)

No Data, yet.

Sorry, no content found under this section.

NovoCure Business

Business models

Product stage

Geographic markets

Products

Sector

Primary:

Target Customer

Core Technology

NovoCure Financials

Total funding Undisclosed

Market cap Undisclosed

Last funding Undisclosed

Funding stage undefined

Total rounds undefined

Investors undefined

Cumulative Funding Raised Over Time ($)

Public Offerings & Exits

Public Offering

$575M

Nov 2020

Stock Exchange

NASDAQ

Valuation Undisclosed

$575M

Initial Public Offering EXIT

$165M

Oct 2015

Stock Exchange

NASDAQ

Valuation $1.8B

$165M

Private Equity Funding

Debt Financing

$100M

May 2024

$100M

Debt Financing

$150M

Feb 2018

1 Investors

$150M

Non-Equity Funding

Grant

$2M

Dec 2018

1 Grantors

$2M

NovoCure Lifecycle

Cumulative Funding Raised Over Time ($)

Timeline

Employees Over Time

News Over Time

Debt Financing

$100M

May 2024

$100M

Stock Exchange

NASDAQ

Valuation Undisclosed

$575M

1 Investors

$2M

Debt Financing

$150M

Feb 2018

1 Investors

$150M

Stock Exchange

NASDAQ

Valuation $1.8B

$165M

News Over Time

News Articles